Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 76Radiotherapy 44pembrolizumab 39Cetuximab 38Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 22Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5Oxaliplatin 5Methotrexate 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Squamous Cell × Pyrimethamine × Clear all
NCT05678348 2025-08-17

Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma

Washington University School of Medicine

Phase EARLY_PHASE1 Completed
22 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡